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This case describes an atypical presentation of molar pregnancy in an emergency department 
patient with abdominal pain and vaginal bleeding. The patient demonstrated clinical features of 
hydatidiform mole, including acute discharge of a large, grape-like vesicular mass, despite multiple 
negative urine pregnancy tests. These false-negative qualitative human chorionic gonadotropin 
assays were likely caused by the “high-dose hook effect” and may have delayed proper care of the 
patient, who displayed pulmonary choriocarcinoma at the time of diagnosis.  [West J Emerg Med. 
2011;12(2):213-215.]
INTRODUCTION
Gestational trophoblastic disease encompasses a spectrum 
of tumors, including complete and partial hydatidiform mole 
(molar pregnancy) and locally invasive or disseminated 
choriocarcinoma.1 Complete hydatidiform mole produces 
characteristic clinical features, including vaginal bleeding and 
uterine size beyond expected gestational age.1 Many other 
clinical features of molar pregnancy, including hyperemesis 
gravidarum, hyperthyroidism and theca lutein ovarian cysts, 
are believed to be induced by markedly elevated serum 
human chorionic gonadotropin (β-hCG) levels produced 
by the trophoblastic tissue.1 Thus, in addition to a complete 
physical and pelvic examination, complete blood count 
(CBC), blood chemistry and pelvic ultrasound, a hallmark 
of diagnosing hydatidiform mole is a positive β-hCG assay 
pregnancy test. Interestingly, sandwich chromatographic 
immunoassays, such as qualitative β-hCG assays, may 
produce false-negative results in the presence of excessively 
high antigen concentrations in a phenomenon known as the 
“high-dose hook effect.” We report a case of molar pregnancy 
and subsequent malignant choriocarcinoma presenting as 
abdominal pain and vaginal spotting with multiple false 
negative urine pregnancy tests, ultimately delaying care.  
CASE REPORT
A previously healthy 19-year-old Gravida 0 Para 0 female 
presented to the emergency department (ED) with seven 
weeks of abdominal pain, vaginal spotting, nausea and 
vomiting. The abdominal pain was described as cramping in 
the mid-epigastric and pelvic regions. The patient denied 
fever, dysuria or diarrhea. She was sexually active without 
contraceptive use and described a history of irregular periods 
since menarche but no recent passage of tissue. Four weeks 
before presenting she took a home pregnancy test that was 
negative. Two weeks prior she was seen at a different facility 
where she had a negative urine pregnancy test and a pelvic 
examination that revealed tenderness. At that time she was 
treated with azithromycin and ceftriaxone for presumed 
cervicitis, but her symptoms continued.  
The physical examination revealed an oral temperature 
of 98.3° F, heart rate of 99 beats/min, respiratory rate of 16 
breaths/min, blood pressure of 169/96 mmHg and oxygen 
saturation of 100% on room air. She was alert and oriented 
but uncomfortable with pain and retching. The cardiac exam 
was normal, and the lungs were clear. The abdomen was 
diffusely tender but soft without rebound or guarding. In the 
lower abdomen, a firm, palpable uterus was present. Pelvic 
examination revealed a closed cervical os with blood clots 
in the vaginal vault and a 20-week sized uterus with cervical 
motion and adenexal tenderness. The patient was noted to 
have no tenderness at the costovertebral angles, no lower 
extremity edema, and no focal neurologic deficits. Point-
of-care and laboratory qualitative urine β-hCG assays were 
negative. A pelvic ultrasound, CBC, blood chemistries and 
quantitative serum β-hCG were ordered. The patient was 
treated with analgesics and anti-emetics. As she was being Volume XII, no. 2  :  May 2011    214  Western Journal of Emergency Medicine
prepared for transport to the ultrasound suite, the patient 
discharged a large, fleshy, vesicular mass followed by profuse 
vaginal bleeding. Subsequent pathological examination 
of this mass found it to  be a 777 gm, 20 x 15 x 16 cm 
aggregate of placental tissue mixed with abundant grape-like 
vesicular tissue and blood clot without fetal parts. Hemostasis 
was achieved with packing. Two large bores were placed 
intravenously, and a blood type and cross was performed for 
transfusion.  An obstetrical/gynecological consult was called 
immediately. At this point the quantitative serum β-hCG level 
returned at 1,370,128 mIU/mL (normal <5-200,000).  Initial 
complete blood count showed white blood cell count of 14.6 
k/mm3 and hemoglobin of 11.1 g/dL with a normal platelet 
count. Her coagulation and basic metabolic panels were within 
normal limits; however, her free thyroxine was elevated 
at 3.43 ng/mL (normal 0.00-0.05), with a corresponding 
low thyroid stimulating hormone level of 0.12 uIU/mL 
(normal 0.34-5.60). Once stabilized, she had an ultrasound 
showing enlarged uterus measuring 19.4 x 9.2 x 8.7 cm and a 
complex mass within the endometrium measuring 16.7 x 6.9 
x 6.3 cm with small hypoechoic areas suspicious for molar 
pregnancy. There was also sonographic evidence of bilaterally 
enlarged ovaries with abundant cysts. She was taken to 
the operating room for emergent dilatation and curettage, 
which demonstrated hydatidiform mole. She was treated 
with blood transfusions for acute anemia, magnesium sulfate 
for pre-eclampsia and beta-blockers for hyperthyroidism. A 
subsequent work-up showed numerous pulmonary nodules in 
bilateral lungs likely due to metastatic choriocarcinoma. The 
patient had an uneventful hospital course and was discharged 
two days post operatively on Depo-Provera and Labetalol with 
instructions to follow up daily for methotrexate treatment. 
After completing chemotherapy, she was followed as an 
outpatient by the gynecological oncology team with serum 
β-hCG screening performed on a regular basis. One year after 
this presentation, the patient had complete remission of her 
choriocarcinoma.
DISCUSSION
Molar pregnancy is an uncommon cause of abdominal 
pain and vaginal bleeding in the ED that may lead to serious 
disseminated disease and death if left untreated. Molar 
pregnancy occurs in approximately one in 1,000 pregnancies 
in the United States. It is most commonly associated with 
pregnancy in the early (15-20 years old) and late (>35 years 
old) reproductive periods.1-2 Hydatidiform moles are an 
anomalous growth of trophoblastic tissue categorized as 
complete or partial. Complete moles have diploid karyotype of 
solely paternal origin and a complete absence of fetal tissue. 1 
Partial moles are characterized by triploid karyotype of both 
maternal and paternal origin and the presence of fetal/
embryonic tissue.1 A retrospective analysis of molar 
pregnancies reported that 75% of patients present with vaginal 
bleeding, while 54% present with enlarged uterus for 
gestational dates and 100% had excessively elevated β-hCG 
levels.2 Here, we report a case of molar pregnancy and 
metastatic choriocarcinoma with multiple negative qualitative 
urine β-hCG pregnancy tests despite an extremely elevated 
serum β-hCG level.  
Clinical decision-making regarding women of 
childbearing age with abdominal pain and vaginal bleeding is 
often dictated by pregnancy testing, specifically point-of-care 
qualitative urine hCG assays. These screening tools, along 
with over-the-counter home pregnancy tests, are 
chromatographic sandwich immunoassays in which two 
antibodies directed to different portions (for example, the α 
and β subunits) of the hCG molecule sandwich a single 
antigen to produce color change. Our ED uses the Clinitest® 
hCG Pregnancy Test from Siemens Healthcare Diagnostic Inc. 
for point-of-care testing. This lateral flow, chromatographic 
assay is reported to produce positive results with hCG 
concentrations ≥25 mIU/mL. A urine sample placed on the 
membrane reacts with migratory colloidal gold particles 
coated with anti-β-hCG antibodies. These antibody-bound 
particles then migrate by capillary action to the fixed detection 
line coated with either anti-α-hCG or goat-anti-mouse 
antibody (control). To induce color change a single hCG 
molecule must be bound by the antibodies to both subunits, 
forming a “sandwich” that attaches the gold particles for color 
change and binds the compound to the detection line. Despite 
the high sensitivity and specificity of the assay, our patient had 
repeatedly negative urine pregnancy tests at home, in an 
outside facility, and upon presentation to our ED. One 
explanation for the negative pregnancy test is the “high-dose 
hook effect,” a rare phenomenon that occurs in sandwich 
immunoassays when the concentration of the antigen is 
sufficiently high to saturate both the solid migratory phase and 
fixed detection antibodies independently.3 In this case, 
excessive levels of free antigen in the sample allow the 
anti-β-hCG and anti-α-hCG antibodies to each bind subunits 
of different hCG molecules rather than subunits of the same 
molecule, preventing them from forming the “sandwich.” As a 
result, the gold particle necessary for color change is never 
bound, leading to a false-negative test. A 1:10 to 1:1000 
dilution of the antigen sample may overcome the hook effect 
by reducing the concentration and allowing the antibodies to 
properly bind to two portions of the same molecule. 4-5
There have been reports of false-negative urine, serum 
and both urine and serum β-hCG pregnancy tests in 
hydatidiform mole. 6-11 In each of these reports, the serum 
β-hCG levels were determined to be greater than 1,000,000 
mIU/mL, and the likely cause for false negative results were 
reported to be the “high-dose hook effect.”6-11 Those cases 
with false-negative serum assays required dilution of the 
samples and re-testing after ultrasound demonstrated 
sonographic evidence of molar pregnancy.9-11 In some reports, 
the diagnosis of molar pregnancy was already suspected prior 
to the false-negative test because of ultrasound evidence or a 
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previous positive pregnancy test.6,7,10,11 In our case, the patient 
discharged a large, vesicular mass characteristic of 
hydatidiform mole prior to the completion of quantitative 
β-hCG testing or ultrasound evaluation. A retrospective 
analysis has suggested that the positive predictive value of 
transvaginal ultrasound for molar pregnancy is 100%.2   
However, often this procedure is delayed or not considered 
when a pregnancy test is negative, as was likely the case when 
our patient was initially seen at an outside facility. Since her 
screening pregnancy test was negative, an ultrasound was 
never performed, making the correct diagnosis difficult. These 
rare reports underscore the importance of quantitative β-hCG 
assays and sonographic evaluation in patients with negative 
pregnancy tests where clinical suspicion of pregnancy remains 
high.  
Management of molar pregnancy in the ED is largely 
supportive and dependent on disease severity. Abdominal 
pain and vaginal bleeding are caused by the mass of 
trophoblastic tissue and fragile surrounding blood vessels.1 
Hyperemesis, hyperthyroidism and ovarian cysts are thought 
to be derived from excessive serum β-hCG levels secreted 
from trophoblastic tissue.1 Therefore, the definitive treatment 
is either hysterectomy or dilation and curettage. Initial 
therapy consists of stabilization, hemostasis if indicated, 
analgesics and anti-emetics. Beta-blockers may be used for 
symptoms of hyperthyroid state.  Some molar pregnancies 
will induce pre-eclampsia, which should be managed with 
magnesium sulfate, but true eclampsia is extremely rare in 
this patient population.1 Choriocarcinoma may present as 
locally invasive non-metastatic or diffuse metastatic disease.1 
The World Health Organization (WHO) prognostic index 
score is used to determine severity of disease and likely 
response to treatment.12 Nine prognostic factors are scored 
from zero to four to determine low, intermediate or high-risk 
gestational trophoblastic disease.12 A WHO score of less than 
seven is usually treated with single agent chemotherapy, most 
commonly methotrexate.12 A score of seven or higher requires 
combination therapy, typically the EMA-CO regime, including 
etoposide, methotrexate and actinomycin D administered in 
the first week of a two-week cycle, then cyclophosphamide 
and vincristine.12 Post-treatment surveillance includes weekly 
serum β-hCG monitoring until levels become negative, and 
then monthly for six months.12 With appropriate therapy 
survival approaches 100%.1,12
CONCLUSION
Molar pregnancy is an uncommon yet serious condition 
that may cause significant pain, hyperemesis, pre-eclampsia, 
hyperthyroidism and possibly metastatic disease. In addition 
to vaginal bleeding and excessive uterine size, a hallmark of 
diagnosis is elevated β-hCG. However, qualitative β-hCG 
assays may be falsely negative due to the high-dose hook 
effect if serum levels are extremely elevated. When suspicion 
exists for molar pregnancy, sonographic evaluation and 
quantitative β-hCG levels are necessary in the work-up. The 
ED therapy for molar pregnancy is supportive along with 
prompt gynecologic consultation with definitive treatment 
being operative. 
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